Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review
| Autor: | Yaacov Baruch, Matti Waterman, Tarek Saadi, Heba Yassin |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Drug
hepatotoxicity medicine.medical_specialty Pathology endocrine system diseases Hepatocellular Liver Injury media_common.quotation_subject Case Report Gastroenterology Cholestasis Internal medicine medicine Elderly patient media_common Liver injury business.industry digestive oral and skin physiology nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine medicine.disease Metformin hepatocellular liver injury metformin cholestasis business medicine.drug |
| Zdroj: | International Journal of General Medicine |
| ISSN: | 1178-7074 |
| DOI: | 10.2147/ijgm.s49657 |
| Popis: | Introduction Metformin is a first-line drug choice for the treatment of type 2 diabetes mellitus (DM-2). Metformin-induced hepatotoxicity has rarely been reported. We report on a case of metformin-induced mixed hepatocellular and cholestatic liver injury in an elderly patient with DM-2 as well as review and summarize case reports of metformin hepatotoxicity available in English on the PubMed database. Case After receiving metformin 850 mg/day for 2 weeks, a 78-year-old male presented with a 10-day history of abdominal pain, vomiting, diarrhea, and jaundice. Laboratory analysis showed severe hepatocellular and cholestatic hepatic injury. Other causes for acute liver injury were ruled out. Discontinuation of metformin treatment led to significant subjective improvement after 1 week, and all hepatic abnormalities resolved by 2 months. Conclusion Metformin is an important drug for the treatment of DM-2, which is also used for treatment of patients with fatty liver. It can, however, induce hepatocellular and cholestatic hepatic injury; both physicians and patients should be aware of this potential side effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|